Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase1b, Multiple Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Safety, and Efficacy of ABBV-319 in Subjects With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT06977724 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06977724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06977724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase1b, Multiple Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Safety, and Efficacy of ABBV-319 in Subjects With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
August 26, 2025
Completion date
March 31, 2029
Enrollment
36 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye syndrome, systemic lupus erythematosus